CJC-1295 No Dac
£29.99
CJC‑1295 (No DAC) is a synthetic analog of growth hormone–releasing hormone (GHRH). It is structurally designed to stimulate the GHRH receptor, which plays a role in regulating the release of growth hormone (GH) from the anterior pituitary gland.
CJC‑1295 (No DAC) – Informational Overview
For Research Purposes Only.
What Is CJC‑1295 (No DAC)?
CJC‑1295 (No DAC) is a synthetic analog of growth hormone–releasing hormone (GHRH). It is structurally designed to stimulate the GHRH receptor, which plays a role in regulating the release of growth hormone (GH) from the anterior pituitary gland.
The “No DAC” version does not contain the Drug Affinity Complex (DAC) modification found in another form of CJC‑1295. As a result, it has a shorter half-life compared to the DAC-modified version and is often discussed in research contexts involving pulsatile hormone signaling.
Difference Between CJC‑1295 With DAC vs. No DAC
-
CJC‑1295 with DAC: Includes a Drug Affinity Complex that binds to albumin, extending circulation time and prolonging biological activity.
-
CJC‑1295 (No DAC): Lacks this modification, resulting in shorter activity duration and pharmacokinetic profile more similar to native GHRH analogs.
This distinction is relevant in endocrine and receptor signaling research.
Mechanism of Action (Scientific Context)
CJC‑1295 (No DAC) interacts with GHRH receptors located in the pituitary gland. In research settings, GHRH analogs are studied for their influence on:
-
Growth hormone secretion patterns
-
Insulin-like growth factor 1 (IGF‑1) signaling
-
Endocrine feedback loops
-
Pituitary receptor dynamics
It is important to note that much of the available data comes from early-stage or experimental studies.
Regulatory Status
-
CJC‑1295 (No DAC) is not approved by the U.S. Food and Drug Administration (FDA) for medical use.
-
It is considered an investigational or research compound.
-
Any product marketed outside regulated pharmaceutical channels may vary in quality, purity, and sterility.
There are no standardized medical dosing guidelines because it is not an approved therapeutic agent.
Important Notice
This page is provided for informational and scientific purposes only.
CJC‑1295 (No DAC) is an investigational peptide and is not approved for therapeutic, diagnostic, or cosmetic use. Individuals should consult licensed healthcare professionals regarding any medical concerns.
| Dose |
10mg ,20mg ,30mg |
|---|
Related products
5 Amino 1MQ
Ipamorelin
Melanotan 2
MOTS-C
Retatrutide
Retatrutide is an investigational peptide drug that acts as a triple receptor agonist, targeting:
-
GLP-1 (glucagon-like peptide-1) receptors – influence glucose regulation and appetite
-
GIP (glucose-dependent insulinotropic polypeptide) receptors – enhance insulin secretion and metabolic signaling
-
Glucagon receptors – modulate energy expenditure and lipid metabolism

Reviews
There are no reviews yet.